Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater

Baumhoer, Daniel; Zlobec, Inti; Tornillo, Luigi; Dietmaier, Wolfgang; Wuensch, Peter H.; Hartmann, Arndt; Sessa, Fausto; Ruemmele, Petra; Terracciano, Luigi

doi:10.1007/s00428-008-0669-7

Cited by 17 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-eight studies reported HER2 positivity assessed by IHC (Table 3); two studies did not perform HER2 IHC analysis [66, 85]. Technical details regarding this assessment were available for 37 of the 38 studies: in the remaining study, this data was not available [71].…”

Section: Resultsmentioning

confidence: 99%

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Galdy

Lamarca

McNamara

et al. 2016

Cancer Metastasis Rev

139

View full text Add to dashboard Cite

Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been reported as predictive markers for HER2-targeted therapy in breast and gastric cancer, whereas human epidermal growth factor receptor 3 (HER3) is emerging as a potential resistance factor. The aim of this study was to perform a systematic review and meta-analysis of the HER2 and HER3 overexpression and amplification in biliary tract cancers (BTCs). An electronic search of MEDLINE, American Society of Clinical Oncology (ASCO), European Society of Medical Oncology Congress (ESMO), and American Association for Cancer Research (AACR) was performed to identify studies reporting HER2 and/or HER3 membrane protein expression by immunohistochemistry (IHC) and/or gene amplification by in situ hybridization (ISH) in BTCs. Studies were classified as “high quality” (HQ) if IHC overexpression was defined as presence of moderate/strong staining or “low quality” (LQ) where “any” expression was considered positive. Of 440 studies screened, 40 met the inclusion criteria. Globally, HER2 expression rate was 26.5 % (95 % CI 18.9–34.1 %). When HQ studies were analyzed (n = 27 studies), extrahepatic BTCs showed a higher HER2 overexpression rate compared to intrahepatic cholangiocarcinoma: 19.9 % (95 % CI 12.8–27.1 %) vs. 4.8 % (95 % CI 0–14.5 %), respectively, p value 0.0049. HER2 amplification rate was higher in patients selected by HER2 overexpression compared to “unselected” patients: 57.6 % (95 % CI 16.2–99 %) vs. 17.9 % (95 % CI 0.1–35.4 %), respectively, p value 0.0072. HER3 overexpression (4/4 HQ studies) and amplification rates were 27.9 % (95 % CI 9.7–46.1 %) and 26.5 % (one study), respectively. Up to 20 % of extrahepatic BTCs appear to be HER2 overexpressed; of these, close to 60 % appear to be HER2 amplified, while HER3 is overexpressed or amplified in about 25 % of patients. Clinical relevance for targeted therapy should be tested in prospective clinical trials.

show abstract

Section: Resultsmentioning

confidence: 99%

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Galdy

Lamarca

McNamara

et al. 2016

Cancer Metastasis Rev

139

View full text Add to dashboard Cite

show abstract

“…Patients' characteristics have been previously described by our study group 30 31. Briefly, the files of the Institute of Pathology, University Hospital Basel (Switzerland), the Institute of Pathology, University of Regensburg (Germany), the Institute of Pathology Nuernberg and the Anatomic Pathology Unit, Department of Human Morphology, University of Insubria, Varese (Italy), were searched for adenomas or carcinomas of the ampulla of Vater over the period from 1985 to 2005.…”

Section: Methodsmentioning

confidence: 99%

“…TMAs were constructed from formalin-fixed and paraffin-embedded specimens using a custom-built instrument (Beecher Instruments, Silver Spring, Maryland, USA) as previously described 30 31. Briefly, H&E-stained sections were obtained from each selected primary block (donor block) to define representative tissue regions.…”

Section: Methodsmentioning

confidence: 99%

Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater

et al. 2011

Self Cite

View full text Add to dashboard Cite

Background Carcinomas of the Vaterian system are rare and presumably arise from pre-existing adenomas. According to the cancer stem cell (CSC) hypothesis, only a small subset of tumor cells has the ability to initiate and develop tumor growth. In colorectal cancer, CD44, CD133, CD166 and EpCAM have been proposed to represent CSC marker proteins and their expression has been shown to correlate with patient survival. Aims To evaluate a potential role of these CSC proteins in tumors of the ampulla of Vater, we investigated their expression in 175 carcinoma, 111 adenoma and 152 normal mucosa specimens arranged in a Tissue Microarray format. Materials and methods Membranous immunoreactivity for each protein marker was scored semi-quantitatively by evaluating the number of positive tumor cells over the total number of tumor cells. Median protein expression levels were used as cut-off scores to define protein marker positivity. Clinical data including survival time were obtained by retrospective analysis of medical records, tumor registries or direct contact.

show abstract

“…For immunohistochemical analyses, a total of 6 arrays with up to 529 cores were constructed from formalin-fixed, paraffinembedded archival tumor tissues using a semi-automated tissue arrayer 25,26 or a manual device (Beecher Instruments, Silver Springs, MD, USA) as previously described. 27 Briefly, hematoxyline/eosinstained slides of all tumors were evaluated by 1 pathologist (P.R.)…”

Section: Tma Constructionmentioning

confidence: 99%

Hepatocyte Nuclear Factor (HNF) 4α Expression Distinguishes Ampullary Cancer Subtypes and Prognosis After Resection

Ehehalt¹,

Rümmele

Kersting³

et al. 2011

Annals of Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater

Cited by 17 publications

References 32 publications

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater

Hepatocyte Nuclear Factor (HNF) 4α Expression Distinguishes Ampullary Cancer Subtypes and Prognosis After Resection

Contact Info

Product

Resources

About